Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus

Author(s): Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, et al.


Context: Visfatin (also known as pre-B cell colony-enhancing factor or PBEF) is a cytokine that is highly expressed in visceral fat and whose blood levels correlate with obesity. Originally isolated as a secreted factor that promotes the growth of B cell precursors and recently found to act as an insulin analog on the insulin receptor, its pathophysiological role in humans remains largely unknown.

Objectives: In this study we investigated whether plasma visfatin level is altered in patients with type 2 diabetes mellitus (T2DM).

Design and patients: Plasma visfatin as well as adiponectin and resistin concentrations were measured through ELISA in type 2 diabetic and nondiabetic subjects.

Results: A total of 61 patients with T2DM and 59 sex- and age-matched nondiabetic subjects were studied. Plasma visfatin was found to be elevated in patients with T2DM (31.9 +/- 31.7 vs. 15.8 +/- 16.7 ng/ml, P = 0.002). In contrast, adiponectin was decreased (4.3 +/- 2.5 vs. 30.8 +/- 10.3 microg/ml, P < 0.001), whereas plasma resistin level did not differ between the groups. Increasing concentrations of visfatin were independently and significantly associated with T2DM. Multiple logistic regression analysis revealed visfatin as an independent association factor for T2DM, even after full adjustment of known biomarkers. The association between adiponectin and T2DM was no longer significant after adjustments for body mass index or waist to hip ratio. In a multiple linear regression analysis, only waist to hip ratio was independently associated with plasma visfatin level.

Conclusion: Our results indicate that visfatin may play a role in the pathogenesis of T2DM.

Similar Articles

Visfatin/PBEF and Atherosclerosis-Related Diseases

Author(s): Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mikhailidis DP

Age of onset and type of diabetes

Author(s): Laakso M, Pyorala K

Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients

Author(s): Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, et al.

Leptin increase is associated with markers of the hemostatic system in obese healthy women

Author(s): Guagnano MT, Romano M, Falco A, Nutini M, Marinopiccoli M, et al.

Effect of exercise training on plasma visfatin and eotaxin levels

Author(s): Choi KM, Kim JH, Cho GJ, Baik SH, Park HS, et al.

Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children

Author(s): Araki S, Dobashi K, Kubo K, Kawagoe R, Yamamoto Y, et al.

An evaluation of visfatin levels in obese subjects

Author(s): Kaminska A, Kopczynska E, Bronisz A, Zmudzinska M, Bielinski M, et al.

Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding

Author(s): Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, et al.

Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass

Author(s): García-Fuentes E, García-Almeida JM, García-Arnés J, García-Serrano S, Rivas-Marín J, et al.

The visfatin gene is associated with glucose and lipid metabolism in a Chinese population

Author(s): Jian WX, Luo TH, Gu YY, Zhang HL, Zheng S et al.

Serum visfatin increases with progressive beta-cell deterioration

Author(s): López-Bermejo A, Chico-Julià B, Fernàndez-Balsells M, Recasens M, Esteve E, et al.

Adipose tissue as an endocrine organ

Author(s): Kershaw EE, Flier JS

Obesity, hypertension and insulin resistance

Author(s): Sharma AM, Chetty VT

Regulation of adipocytokines and insulin resistance

Author(s): Fasshauer M, Paschke R